The SATELLITE trial 160 investigated the use in HFpEF of mitiperstat, a myeloperoxidase inhibitor and showed a trend for symptomatic improvement.
← all excerpts
Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology.
1
—
—